Pralatrexate for refractory mycosis fungoides in two Japanese patients

Pralatrexate has been approved for the treatment of relapsed/refractory peripheral T cell lymphomas. Studies in the U.S. also support the clinical efficacy of pralatrexate to treat advanced‐stage cutaneous T‐cell lymphomas, but outcomes in Japanese patients have not yet been reported. We herein desc...

Full description

Saved in:
Bibliographic Details
Published inJournal of dermatology Vol. 48; no. 5; pp. 667 - 671
Main Authors Teraishi, Mika, Oguro, Tokuko, Kusume, Ema, Kobashi, Haruka, Sano, Hozumi, Fujioka, Ai, Yamamoto, Mayuko, Nakajima, Hideki, Sano, Shigetoshi
Format Journal Article
LanguageEnglish
Published England Wiley Subscription Services, Inc 01.05.2021
John Wiley and Sons Inc
Subjects
Aminopterin - analogs & derivatives
Case reports
Chemotherapy
Clinical outcomes
Concise Communication
Concise Communications
cutaneous T‐cell lymphoma
Fungal infections
Humans
Japan
Lymphocytes T
Lymphoma
Mycosis
Mycosis fungoides
Mycosis Fungoides - drug therapy
Neoplasm Recurrence, Local
Patients
pralatrexate
refractory mycosis fungoides
Skin Neoplasms - drug therapy
Japan
refractory mycosis fungoides
pralatrexate
chemotherapy
cutaneous T-cell lymphoma
Online AccessGet full text

Cover

More Information
Summary:Pralatrexate has been approved for the treatment of relapsed/refractory peripheral T cell lymphomas. Studies in the U.S. also support the clinical efficacy of pralatrexate to treat advanced‐stage cutaneous T‐cell lymphomas, but outcomes in Japanese patients have not yet been reported. We herein describe two Japanese patients with heavily‐pretreated relapsed/refractory mycosis fungoides that were successfully controlled by pralatrexate.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0385-2407
1346-8138
DOI:10.1111/1346-8138.15761